Resona Asset Management Co. Ltd. Buys 22,595 Shares of Danaher Corporation $DHR

Resona Asset Management Co. Ltd. increased its stake in shares of Danaher Corporation (NYSE:DHR) by 4.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 513,288 shares of the conglomerate’s stock after purchasing an additional 22,595 shares during the quarter. Resona Asset Management Co. Ltd.’s holdings in Danaher were worth $100,071,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of the stock. Norges Bank bought a new position in Danaher in the 2nd quarter valued at $1,979,503,000. Viking Global Investors LP lifted its stake in shares of Danaher by 543.9% during the second quarter. Viking Global Investors LP now owns 2,907,515 shares of the conglomerate’s stock valued at $574,351,000 after acquiring an additional 2,455,994 shares during the period. Generation Investment Management LLP boosted its holdings in Danaher by 56.2% in the second quarter. Generation Investment Management LLP now owns 4,965,646 shares of the conglomerate’s stock valued at $980,914,000 after acquiring an additional 1,787,522 shares during the last quarter. Primecap Management Co. CA raised its holdings in Danaher by 924.2% during the 2nd quarter. Primecap Management Co. CA now owns 1,239,320 shares of the conglomerate’s stock worth $244,815,000 after purchasing an additional 1,118,318 shares during the last quarter. Finally, Vanguard Group Inc. lifted its position in Danaher by 1.3% during the 2nd quarter. Vanguard Group Inc. now owns 60,769,587 shares of the conglomerate’s stock valued at $12,004,424,000 after purchasing an additional 788,499 shares during the period. Institutional investors own 79.05% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on DHR shares. The Goldman Sachs Group boosted their price target on shares of Danaher from $265.00 to $270.00 and gave the stock a “buy” rating in a research note on Tuesday. JPMorgan Chase & Co. lifted their target price on shares of Danaher from $260.00 to $270.00 and gave the stock an “overweight” rating in a report on Wednesday, October 22nd. Argus set a $265.00 price target on Danaher in a research note on Wednesday, January 14th. Guggenheim raised their price target on Danaher from $250.00 to $275.00 and gave the stock a “buy” rating in a research report on Friday, January 2nd. Finally, Jefferies Financial Group lifted their price objective on Danaher from $245.00 to $255.00 and gave the stock a “buy” rating in a research note on Wednesday, December 17th. Twenty equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $252.09.

Insider Activity

In related news, SVP Brian W. Ellis sold 21,776 shares of the business’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $219.23, for a total value of $4,773,952.48. Following the completion of the transaction, the senior vice president directly owned 14,553 shares in the company, valued at approximately $3,190,454.19. The trade was a 59.94% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Georgeann Couchara sold 5,174 shares of the stock in a transaction that occurred on Monday, November 10th. The stock was sold at an average price of $210.42, for a total value of $1,088,713.08. Following the sale, the senior vice president directly owned 2,625 shares of the company’s stock, valued at approximately $552,352.50. The trade was a 66.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 30,248 shares of company stock worth $6,609,663 in the last 90 days. Corporate insiders own 11.10% of the company’s stock.

Danaher Trading Down 2.2%

Shares of NYSE DHR opened at $234.91 on Friday. Danaher Corporation has a twelve month low of $171.00 and a twelve month high of $258.23. The stock has a market cap of $165.93 billion, a price-to-earnings ratio of 48.43, a P/E/G ratio of 3.65 and a beta of 0.89. The company has a quick ratio of 1.10, a current ratio of 1.52 and a debt-to-equity ratio of 0.33. The company’s fifty day moving average is $230.26 and its 200-day moving average is $213.09.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Monday, October 20th. The conglomerate reported $1.89 EPS for the quarter, topping the consensus estimate of $1.72 by $0.17. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The business had revenue of $6.05 billion for the quarter, compared to the consensus estimate of $6 billion. During the same quarter last year, the business posted $1.71 EPS. The firm’s revenue was up 4.4% compared to the same quarter last year. Equities research analysts predict that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 30th. Stockholders of record on Friday, December 26th will be given a dividend of $0.32 per share. The ex-dividend date of this dividend is Friday, December 26th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.5%. Danaher’s dividend payout ratio (DPR) is currently 26.39%.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.